Morning Edition
Waking up is hard to do, but it's easier with NPR's Morning Edition. Morning Edition provides news in context, airs thoughtful ideas and commentary, and reviews important new music, books, and events in the arts. All with voices and sounds that invite listeners to experience the stories. Locally hosted by Rick Ganley.
More information is available at the Morning Edition website found here.
-
Israel has not claimed explicit responsibility for the attacks. NPR's Steve Inskeep talks to Aaron David Miller, former State Department negotiator, about what's the strategy behind the attacks.
-
Trump can now start selling his majority stake in the Truth Social parent company, as a lockup on insider sales expires. But that could tank the price of the stock.
-
In Lebanon, victims were buried after a cyberattack Tuesday that detonated thousands of hand-held pagers used by the militant group Hezbollah. The next day there was a second wave of attacks.
-
The explosions in Lebanon are the latest in a series of lethal attacks attributed to Israel, and carried out against its leading enemies in their heavily guarded capitals.
-
Labor unions have been active in the presidential campaign this cycle, but the Teamsters -- a large, prominent union -- says it won't endorse either Donald Trump or Kamala Harris. Why?
-
The highest-earning YouTuber, MrBeast, is facing a lawsuit after contestants on his Amazon reality show claimed he mistreated them. NPR's Steve Inskeep speaks with "Variety" reporter Todd Spangler.
-
A new study finds more than 3,000 chemicals used in food packaging are getting into people's bodies. Some — including BPA, phthalates and PFAS — have clear health concerns; others are unstudied.
-
Is the U.S. banning TikTok essentially censorship? NPR's Leila Fadel speaks with an attorney whose firm filed a petition on behalf of a TikTok creator seeking to stop the U.S. ban.
-
Former President Jimmy Carter receives one more award -- this time for his writing. NPR's Steve Inskeep talks to his grandson Jason Carter.
-
It’s been almost a year since the Food and Drug Administration approved the first genetic treatments for sickle cell disease. So far, only a few patients have received the long-awaited treatments.
You make NHPR possible.
NHPR is nonprofit and independent. We rely on readers like you to support the local, national, and international coverage on this website. Your support makes this news available to everyone.
Give today. A monthly donation of $5 makes a real difference.